Stefan Stefanovic
Overview
Explore the profile of Stefan Stefanovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
223
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Stefanovic S, Deutsch T, Wirtz R, Hartkopf A, Sinn P, Kohler M, et al.
Diagnostics (Basel)
. 2020 Jun;
10(6).
PMID: 32512707
Breast cancers (BC) can mutate, allowing metastatic tumors (MT) to sometimes differ to primary tumors (PT) in gene expression. Despite contemporary metastatic breast cancer (MBC) therapy, subtype conversion seems prognostically...
12.
Deutsch T, Stefanovic S, Feisst M, Fischer C, Riedel F, Fremd C, et al.
Cancers (Basel)
. 2020 Apr;
12(4).
PMID: 32344685
Detection of circulating tumor cells (CTC) can distinguish between aggressive and indolent metastatic disease in breast cancer patients and is thus considered an independent, negative prognostic factor. A clear decline...
13.
Stefanovic S, Deutsch T, Riethdorf S, Fischer C, Hartkopf A, Sinn P, et al.
Int J Mol Sci
. 2020 Apr;
21(6).
PMID: 32245182
Circulating tumor cell (CTC) detection is a prognostic factor in the metastatic breast cancer (MBC) setting. Discrepancies in primary (PT) and metastatic tumor (MT) genetic profiles are also of prognostic...
14.
Stefanovic S, Deutsch T, Wirtz R, Hartkopf A, Sinn P, Schuetz F, et al.
Cancers (Basel)
. 2019 Mar;
11(3).
PMID: 30862027
The presence of circulating tumor cells (CTCs), detected as a form of liquid biopsy is associated with poor survival in both early and metastatic breast cancer. Monitoring tumor biology based...
15.
Stefanovic S, Wirtz R, Deutsch T, Hartkopf A, Sinn P, Varga Z, et al.
Oncotarget
. 2017 Sep;
8(31):51416-51428.
PMID: 28881657
Biomarker changes between primary (PT) and metastatic tumor (MT) site may be significant in individualizing treatment strategies and can result from actual clonal evolution, biomarker conversion, or technical limitations of...
16.
Schutz F, Stefanovic S, Mayer L, von Au A, Domschke C, Sohn C
Oncol Res Treat
. 2017 Mar;
40(5):294-297.
PMID: 28346916
The programmed cell death-1 receptor (PD-1) is an immune checkpoint inhibitor which is expressed on the surface of immune effector cells. It is activated mainly by PD-L1 which can be...
17.
Stefanovic S, Wallwiener M, Karic U, Domschke C, Katic L, Taran F, et al.
Support Care Cancer
. 2016 Oct;
25(2):549-558.
PMID: 27747478
Purpose: The capture of adequate treatment outcomes and quality of life (QOL) of advanced breast cancer patients in clinical routine represents a great challenge. Patient-reported outcomes (PROs) are data elements...
18.
Deutsch T, Riethdorf S, Nees J, Hartkopf A, Schonfisch B, Domschke C, et al.
Breast Cancer Res Treat
. 2016 Oct;
160(2):277-290.
PMID: 27696083
Purpose: While intact circulating tumor cells (iCTC) have independent negative prognostic impact on patients with metastatic breast cancer (MBC), the prognostic relevance of apoptotic CTC (aCTC) has not been validated...
19.
von Au A, Milloth E, Diel I, Stefanovic S, Hennigs A, Wallwiener M, et al.
Onco Targets Ther
. 2016 Jul;
9:4173-80.
PMID: 27468239
Purpose: Patients with metastasized breast cancer often suffer from discomfort caused by metastatic bone disease. Thus, osteoprotection is an important part of therapy in breast cancer metastasized to bone, and...
20.
Domschke C, Schneeweiss A, Stefanovic S, Wallwiener M, Heil J, Rom J, et al.
Breast Care (Basel)
. 2016 May;
11(2):102-7.
PMID: 27239171
More recently, immunotherapy has emerged as a novel potentially effective therapeutic option also for solid malignancies such as breast cancer (BC). Relevant approaches, however, are determined by the 2 main...